CLEC10A and hepatocellular carcinoma: In particular, the consistent expression of lncMER52A and HERV-K (HML-2) RNA in HCC lesions provides a strong rationale for the development of novel HCC-specific biomarkers, as well as therapeutic targets based on HERVs.